1. Search Result
Search Result
Results for "

USP

" in MedChemExpress (MCE) Product Catalog:

308

Inhibitors & Agonists

1

Screening Libraries

30

Biochemical Assay Reagents

2

Peptides

6

Natural
Products

62

Recombinant Proteins

1

Isotope-Labeled Compounds

16

Antibodies

153

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13487
    USP7/USP47 inhibitor
    3 Publications Verification

    Deubiquitinase Cancer
    USP7/USP47 inhibitor is a selective ubiquitin-specific protease 7/47 (USP7/USP47) inhibitor, with EC50s of 0.42 μM and 1.0 μM, respectively.
    USP7/USP47 inhibitor
  • HY-136910

    USP7-IN-7

    Deubiquitinase MDM-2/p53 Cancer
    USP7-797 (USP7-IN-7) is an orally available, selective USP7 inhibitor (IC50=0.5 nmol/L) with antitumor activity. USP7-797 reduces the level of MDM2, thereby increasing the stability and activity of p53, leading to cell cycle arrest and apoptosis. USP7-797 has low nanomolar cytotoxicity against p53 mutant cancer cell lines, p53 wild-type hematological tumors, and neuroblastoma cell lines .
    USP7-797
  • HY-134817
    USP7-IN-8
    1 Publications Verification

    Deubiquitinase Cancer
    USP7-IN-8 (example 81) is a selective ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 1.4 μM in an Ub-Rho110 assay. USP7-IN-8 shows no activity against USP47 and USP5. USP7-IN-8 has anticancer effects .
    USP7-IN-8
  • HY-149230

    Deubiquitinase Cancer
    USP28-IN-4 is a USP28 inhibitor (IC50=0.04 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-4 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-4 also decreases the ankyrase-1/2 level in vitro. USP28-IN-4 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .
    USP28-IN-4
  • HY-149229

    Deubiquitinase Cancer
    USP28-IN-3 is a USP28 inhibitor (IC50=0.1 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-3 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-3 also decreases the ankyrase-1/2 level in vitro. USP28-IN-3 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .
    USP28-IN-3
  • HY-148184

    Deubiquitinase Cancer
    USP1-IN-3 is a selective USPI inhibitor. USP1-IN-3 inhibits USPI-UAFI with an IC50 value of <30 nM. USP1-IN-3 can be used for the research of cancer .
    USP1-IN-3
  • HY-111166

    Deubiquitinase Cancer
    USP7/USP47 inhibitor 1 (compound 2) is an inhibitor of USP47, with an EC50 of 14 μM. USP7/USP47 inhibitor 1 has an EC50 of >31.6 μM for USP7. USP7/USP47 inhibitor 1 can be used for cancer research .
    USP7/USP47 inhibitor 1
  • HY-164544

    Deubiquitinase Cancer
    USP7-055 is a USP7 inhibitor. USP7-055 can be used in cancer research .
    USP7-055
  • HY-149228

    Deubiquitinase Cancer
    USP28-IN-2 is a USP28 inhibitor (IC50=0.3 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-2 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-2 also decreases the ankyrase-1/2 level in vitro. USP28-IN-2 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .
    USP28-IN-2
  • HY-174301

    Deubiquitinase DNA Methyltransferase MDM-2/p53 Cancer
    USP7-IN-18 is a naphthalene derivative. USP7-IN-18 is a selective USP7 inhibitor (IC50 : 130.9 nM), with no or very weak inhibition of the other 8 DUBs including USP47. USP7-IN-18 specifically binds to the catalytic domain of USP7, blocking its deubiquitinase activity. USP7-IN-18 causes degradation of the oncogenic proteins MDM2 and DNMT1, and also degrades the novel target PCLAF. USP7-IN-18 activates the p53-p21 pathway. USP7-IN-18 exerts anti-tumor effects in colon cancer animal models and reshapes the tumor immune microenvironment. USP7-IN-18 achieves both direct cytotoxic and immune-synergistic anti-tumor actions.
    USP7-IN-18
  • HY-125015

    Deubiquitinase Cancer
    USP10-IN-1 is a USP10 inhibitor.
    USP10-IN-1
  • HY-163622

    Apoptosis Deubiquitinase Cancer
    USP10-IN-3 (compound D1) is a potent USP10 inhibitor with an IC50 value of 7.2 µM. USP10-IN-3 inhibits cell proliferation. USP10-IN-3 induces apoptosis and cell cycle arrest at S-phase .
    USP10-IN-3
  • HY-161909

    Deubiquitinase Cardiovascular Disease Neurological Disease
    USP30-I-1 is a selective inhibitor of USP30 with an IC50 value of 94 nM. USP30-I-1 can be used in the research of diseases with impaired mitophagy by targeting USP30 .
    USP30-I-1
  • HY-139979
    USP5-IN-1
    2 Publications Verification

    Deubiquitinase Cancer
    USP5-IN-1 (compound 64) is a selective competitive inhibitor of USP5 zinc finger ubiquitin binding domain (ZnF-UBD) (KD=2.8 μM). USP5-IN-1 competitively blocks the binding of ubiquitin to ZnF-UBD, inhibits the catalytic activity of USP5, and thus hinders the hydrolysis of ubiquitin chains. USP5-IN-1 can inhibit USP5 cleavage of Lys48-linked diubiquitin substrates in vitro and is a potential USP5 chemical probe and potential inhibitor of USP5-related cancers.
    USP5-IN-1
  • HY-148046
    USP15-IN-1
    1 Publications Verification

    Deubiquitinase Cancer
    USP15-IN-1 is a potent USP15 inhibitor with an IC50 value of 3.76 μM. USP15-IN-1 can be used for researching anticancer .
    USP15-IN-1
  • HY-161878

    Deubiquitinase Cancer
    USP1-IN-10 (compound 2) is a potent tricyclic USP1 inhibitor with an IC50 of 7.6 nM. USP1-IN-10 inhibits MDA-MB-436 viability (IC50=21.58 nM). USP1-IN-10 has the potential for cancers research .
    USP1-IN-10
  • HY-153942

    Deubiquitinase Cancer
    USP7-IN-12 (compound 1) is a potent and orally active Usp7 inhibitor with an IC50 value of 3.67 nM. USP7-IN-12 shows antiproliferative activity .
    USP7-IN-12
  • HY-176416

    Deubiquitinase Cancer
    USP7-IN-17 (compound M15) is a potent USP7 inhibitor. USP7-IN-17 inhibits HepG2 cell activity with an IC50 of 4.38 μM .
    USP7-IN-17
  • HY-176704

    Deubiquitinase Cancer
    USP1-IN-13 (compound 2) is a potent and orally active USP1 inhibitor with an IC50 value of 0.00102 µM. USP1-IN-13 inhibits cell clone formation .
    USP1-IN-13
  • HY-156525

    Deubiquitinase Cancer
    USP1-IN-6 (compound 11) is a USP1 inhibitor (IC50<50 nM). USP1-IN-5 also inhibits MDA-MB-436 cells with IC50 <50 nM .
    USP1-IN-6
  • HY-112128

    Deubiquitinase MDM-2/p53 Cancer
    USP7-IN-3 (Compound 5) is an effective and selective allosteric inhibitor of ubiquitin-specific protease 7 (USP7). USP7-IN-3 can be used for research on acute lymphoblastic leukemia .
    USP7-IN-3
  • HY-156524

    Deubiquitinase Cancer
    USP1-IN-5 (compound 10) is a USP1 inhibitor (IC50<50 nM). USP1-IN-5 also inhibits MDA-MB-436 cells with IC50 <50 nM .
    USP1-IN-5
  • HY-153731

    Deubiquitinase Cancer
    USP1-IN-4 (compound 10) is an effective USP1 inhibitor with an IC50 value of 2.44 nM. USP1-IN-4 has anticancer activity and synergistic activity with various anticancer drugs .
    USP1-IN-4
  • HY-148482

    Deubiquitinase Cancer
    USP7-IN-11 is a potent ubiquitin-specific protease 7 (USP7) (Deubiquitinase) inhibitor with an IC50 of 0.37 nM. USP7-IN-11 has anticancer effects (WO2022048498A1; Example 187) .
    USP7-IN-11
  • HY-147032

    Deubiquitinase Cancer
    USP8-IN-1 is a USP8 inhibitor with an IC50 of 1.9 μM. USP8-IN-1 inhibits H1975 cell growth with a GI50 of 82.04 μM (CN111138358A; U10) .
    USP8-IN-1
  • HY-168121

    Deubiquitinase Cancer
    USP7-IN-15 (compound J21) is a USP7 inhibitor, with an IC50 of 41.35 nM.
    USP7-IN-15
  • HY-161446

    Deubiquitinase Cancer
    USP1-IN-7 (Compound 3) is an inhibitor for ubiquitin specific peptidase 1 (USP1) and its cofactor UAF1, with IC50 ≤50 nM. USP1-IN-7 inhibits proliferation of MDA-MB-436 with IC50 ≤50 nM .
    USP1-IN-7
  • HY-161447

    Deubiquitinase Cancer
    USP1-IN-8 (Compound 16) is an inhibitor for ubiquitin specific peptidase 1 (USP1) and its cofactor UAF1, with IC50 ≤50 nM. USP1-IN-8 inhibits proliferation of MDA-MB-436 with IC50 ≤50 nM .
    USP1-IN-8
  • HY-149901

    Deubiquitinase Cancer
    USP8-IN-2 (Compd U52) is a deubiquitinase USP8 inhibitor with an IC50 value of 6.0 μM. USP8-IN-2 also inhibits the proliferation of H1957 cells with an GI50 value of 24.93 μM, respectively .
    USP8-IN-2
  • HY-122646

    Deubiquitinase MDM-2/p53 Cancer
    USP7-IN-2 (compound 4) is a non-competitive USP7 inhibitor with an IC50 of 6 nM. USP7-IN-2 causes degradation of MDM2, stabilization of p53 and induction of p21 in multiple cell lines, and can be utilized in cancer research .
    USP7-IN-2
  • HY-176703

    Deubiquitinase Cancer
    USP1-IN-12 (compound 4) is a potent and orally activeUSP1 inhibitor with an IC50 value of 0.00366 µM. USP1-IN-12 inhibits cell clone formation .
    USP1-IN-12
  • HY-149902

    Deubiquitinase Cancer
    USP8-IN-3 (Compd U51) is a deubiquitinase USP8 inhibitor with an IC50 value of 4.0 μM. USP8-IN-3 also inhibits the proliferation of GH3 and H1957 cells with GI50s of 37.03 μM and 6.01 μM, respectively .
    USP8-IN-3
  • HY-159964

    Deubiquitinase Cancer
    USP7-IN-16 (Compound 61) is a selective USP7 inhibitor with IC50 values of 5.5 nM in the FLINT assay and 2.1 nM in MM.1S cells. USP7-IN-16 exhibits antitumor activity in mice and is a promising candidate for research in the field of oncology .
    USP7-IN-16
  • HY-148481

    Deubiquitinase Cancer
    USP7-IN-10 (compound 1) is a potent ubiquitin-specific protease 7 (USP7) inhibitor, with an IC50 of 13.39 nM .
    USP7-IN-10
  • HY-148481A

    Deubiquitinase Cancer
    USP7-IN-10 hydrochloride (compound 1) is a potent ubiquitin-specific protease 7 (USP7) inhibitor, with an IC50 of 13.39 nM .
    USP7-IN-10 hydrochloride
  • HY-146887

    Deubiquitinase Apoptosis Cancer
    USP7-IN-9 is a highly potent ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 value of 40.8 nM. USP7-IN-9 can induce apoptosis and arrest cell progression at G0/G1 and S phases in RS4; 11 cells. USP7-IN-9 reduces the protein levels of oncoproteins MDM2 and DNMT1 and increases the protein levels of tumor suppressors p53 and p21 .
    USP7-IN-9
  • HY-49319

    Ligands for Target Protein for PROTAC Cancer
    USP7-IN-14 is a Ligand for target protein for pROTAC.
    USP7-IN-14
  • HY-170921

    Deubiquitinase Cancer
    USP1-IN-11 (compound 38-P2) is a selective, reversible, and noncompetitive USP1 (Ubiquitin-specific protease 1) inhibitor. USP1-IN-11 activates the DDR (DNA damage repair) pathway, induces cell cycle arrest and cell Apoptosis, and inhibits cell survival. USP1-IN-11 enhances the sensitivity of Olaparib (HY-10162)-resistant cells to Olaparib (HY-10162) and shows a synergetic effect with Andrographolide (HY-N0191) in BRCA-proficient cancer cells. USP1-IN-11 displays significant, dose-dependent antitumor efficacy in the MDA-MB-436 xenograft model .
    USP1-IN-11
  • HY-16709
    USP7-IN-1
    5+ Cited Publications

    Deubiquitinase Cancer
    USP7-IN-1 is a selective and reversible inhibitor of ubiquitin-specific protease 7 (USP7), with an IC50 of 77 μM, and can be used for the research of cancer.
    USP7-IN-1
  • HY-162633

    Deubiquitinase Cancer
    USP1-IN-9 (Compound 1m) is reversible and noncompetitive ubiquitin-specific proteases (USP1) inhibitors with an IC50 of 8.8 nM, which is designed and synthesized to pyrido[2,3-d]pyrimidin-7(8H)-one derivative based on the disclosed structure of ML323(HY-17543) and KSQ-4279(HY-145471). USP1-IN-9 displays excellent USP1/UAF inhibition and exhibits strong antiproliferation effect in breast cancer cells. USP1-IN-9 can generate enhanced cell killing with PARP inhibitor olaparib(HY-10162) in olaparib-resistant MDA-MB-436/OP cells, which is promising for research in the field of cancer .
    USP1-IN-9
  • HY-160515

    Deubiquitinase Cancer
    USP7-IN-13 (Compound 101) is a USP7 inhibitor with an IC50 value of 0.2-1 μM, which can be used for the study of multiple myeloma .
    USP7-IN-13
  • HY-148099

    Deubiquitinase Cancer
    USP1-IN-2 (Compound I-193) is a potent ubiquitin-specific protease 1 (USP1) inhibitor with an IC50 of less than about 50 nM .
    USP1-IN-2
  • HY-129169

    Deubiquitinase Cancer
    USP7-IN-6 is a potent ubiquitin specific protease 7 (USP7) inhibitor, extracted from patent WO2017212010A1, example 25, has an IC50 of 6.8 nM .
    USP7-IN-6
  • HY-173352

    Deubiquitinase Cancer
    USP7 activator 1 (compound MS-8) is an activator of USP7 by engaging the allosteric C-terminal binding pocket of USP7 .
    USP7 activator 1
  • HY-145471
    KSQ-4279
    1 Publications Verification

    USP1-IN-1

    Deubiquitinase PARP Cancer
    KSQ-4279 (USP1-IN-1) is a potent USP1 inhibitor and a selective PARP1 inhibitor. KSQ-4279 is promising for research of cancers .
    KSQ-4279
  • HY-117370
    USP25/28 inhibitor AZ1
    2 Publications Verification

    AZ1

    Deubiquitinase Cancer
    USP25/28 inhibitor AZ1 (AZ1) is an orally active, selective, noncompetitive, dual ubiquitin specific protease (USP) 25/28 inhibitor with IC50s of 0.7 μM and 0.6 μM, respectively. USP25/28 inhibitor AZ1 attenuates colitis and tumorigenesis in the mice model .
    USP25/28 inhibitor AZ1
  • HY-111623

    Deubiquitinase Cancer
    USP30 inhibitor 11 is a selective and potent ubiquitin specific peptidase 30 (USP30) inhibitor with an IC50 of 0.01 μΜ, the example 83 extracted from patent WO2017009650A1. USP30 inhibitor 11 is used for the study of cancer and conditions involving mitochondrial dysfunction .
    USP30 inhibitor 11
  • HY-157428

    IKZF Family Others
    USP3 ZnF-UBD ligand-1 (compound 59) is a ligand that binds to the zinc finger ubiquitin-binding domain (ZnF-UBD) of USP3 with a KD of 14 μM .
    USP3 ZnF-UBD ligand-1
  • HY-RS15532

    Small Interfering RNA (siRNA) Others

    USP21 Human Pre-designed siRNA Set A contains three designed siRNAs for USP21 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    USP21 Human Pre-designed siRNA Set A
    USP21 Human Pre-designed siRNA Set A
  • HY-RS27020

    Small Interfering RNA (siRNA) Others

    Usp37 Rat Pre-designed siRNA Set A contains three designed siRNAs for Usp37 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Usp37 Rat Pre-designed siRNA Set A
    Usp37 Rat Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: